Protocol Ledger

Therapeutic Cohort OTH · ClinicalTrials.gov API v2

Rare Genetic, Women's Health, and Other: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 10,777 interventional Phase II and Phase III Rare Genetic, Women's Health, and Other protocols registered from 2018 through 2026, including 3,944 active studies, 3,957 completed studies, and 1,190 early-stopped studies (11.04% overall; 23.12% of closed trials).

Median Enrollment: 60.0 participants Median Completed Span: 572 days California Share: 1,737 studies (16.1%)

1. Reconciled Rare Genetic, Women's Health, and Other Execution & Stop-Cause Profile

Rare Genetic, Women's Health, and Other Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 10,777 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 3,944 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 3,957 / 1,190 23.12% closed-trial attrition ratio across 5,147 closed protocols
Slow Accrual vs Safety & Futility Stops 287 / 125 / 63 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 81.6% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Rare Genetic, Women's Health, and Other

Consolidated Biopharma, Academic & Federal Sponsors (Rare Genetic, Women's Health, and Other Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Assistance Publique - Hôpitaux de Paris Academic / Institutional Sponsor 379 195 88 0
Ain Shams University Academic / Institutional Sponsor 277 60 134 0
Assiut University Academic / Institutional Sponsor 214 61 59 0
Cairo University Academic / Institutional Sponsor 214 44 76 0
Takeda Biopharma Industry 192 63 95 63
Tanta University Academic / Institutional Sponsor 178 72 63 0
Yale University Academic / Institutional Sponsor 146 80 36 0
Stanford University Academic / Cooperative Group 139 69 39 0
Peking University People's Hospital Academic / Institutional Sponsor 135 55 15 0
Bayer Biopharma Industry 107 25 66 98
Mansoura University Academic / Institutional Sponsor 92 26 24 0
Vanderbilt University Medical Center Academic / Institutional Sponsor 81 35 32 0

3. Representative Multi-Center Phase II & III Rare Genetic, Women's Health, and Other Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Rare Genetic, Women's Health, and Other
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07208058 A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Kn TJ Biopharma Co Phase III RECRUITING
NCT07614152 The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature Xiamen Amoytop Biotech Co Phase III RECRUITING
NCT07396480 Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized First Affiliated Hospital of Zhejiang University Phase III RECRUITING
NCT07707687 Safety and Efficacy of Eculizumab in High-risk TA-TMA First Affiliated Hospital of Zhejiang University Phase II RECRUITING
NCT07692841 Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors First Affiliated Hospital of Zhejiang University Phase III RECRUITING
NCT06900920 A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia Chia Tai Tianqing Pharmaceutical Group Co Phase III RECRUITING
NCT05997602 To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH Shanghai Fosun Pharmaceutical Industrial Development Co Phase II RECRUITING
NCT06927310 The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature Xiamen Amoytop Biotech Co Phase III RECRUITING
NCT06747949 A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) Amgen Phase III RECRUITING
NCT07640893 A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease Shanghai RAAS Blood Products Co Phase II RECRUITING
NCT07309562 The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age Xiamen Amoytop Biotech Co Phase III RECRUITING
NCT06937944 Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines JHM BioPharma (Tonghua) Co Phase III RECRUITING
NCT06902558 ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Calico Life Sciences Phase II RECRUITING
NCT06351150 Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock Chia Tai Tianqing Pharmaceutical Group Co Phase III RECRUITING
NCT07710248 SG301-SC Injection Safety Study in Subjects With Primary ITP Patients Hangzhou Sumgen Biotech Co Phase II RECRUITING
NCT07015996 Efficacy of Tezepelumab in Peanut Oral Immunotherapy National Institute of Allergy and Infectious Diseases (NIAID) Phase II RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI